Onasemnogene Abeparvovec and Peginterferon beta-1a
Determining the interaction of Onasemnogene Abeparvovec and Peginterferon beta-1a and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Consumer information for this interaction is not currently available.MONITOR: Coadministration of beta interferons with other agents known to induce hepatotoxicity may potentiate the risk of liver injury. Use of beta interferons has been associated with rare cases of liver injury, including autoimmune hepatitis and severe liver damage leading to hepatic failure, some of which required transplantation. In some cases, these events have occurred in the presence of other drugs that have been associated with hepatic injury. Symptoms of liver dysfunction typically began from 1 to 6 months following the initiation of therapy. Asymptomatic elevation of hepatic transaminases (particularly SGPT) have also been reported but is common with interferon therapy. MANAGEMENT: The risk of hepatic injury should be considered when beta interferons are used with other potentially hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; other interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Liver function tests should be monitored at regular intervals and the interferon dosage reduced if SGPT rises above 5 times the upper limit of normal. The dosage may be gradually re-escalated when enzyme levels return to normal. Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice. If liver injury is suspected, interferon therapy should be promptly discontinued due to the potential for rapid progression to liver failure. References "Product Information. Plegridy (peginterferon beta-1a)." Biogen Idec Inc, Cambridge, MA. "Product Information. Betaseron (interferon beta-1b)." Berlex, Richmond, CA. "Product Information. Rebif (interferon beta-1a)." Serono Laboratories Inc, Norwell, MA. "Product Information. Avonex (interferon beta-1a)." Biogen, Cambridge, MA. View all 4 references
Professional:MONITOR: Coadministration of beta interferons with other agents known to induce hepatotoxicity may potentiate the risk of liver injury. Use of beta interferons has been associated with rare cases of liver injury, including autoimmune hepatitis and severe liver damage leading to hepatic failure, some of which required transplantation. In some cases, these events have occurred in the presence of other drugs that have been associated with hepatic injury. Symptoms of liver dysfunction typically began from 1 to 6 months following the initiation of therapy. Asymptomatic elevation of hepatic transaminases (particularly SGPT) have also been reported but is common with interferon therapy.
MANAGEMENT: The risk of hepatic injury should be considered when beta interferons are used with other potentially hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; other interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Liver function tests should be monitored at regular intervals and the interferon dosage reduced if SGPT rises above 5 times the upper limit of normal. The dosage may be gradually re-escalated when enzyme levels return to normal. Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice. If liver injury is suspected, interferon therapy should be promptly discontinued due to the potential for rapid progression to liver failure.
- "Product Information. Plegridy (peginterferon beta-1a)." Biogen Idec Inc, Cambridge, MA.
- "Product Information. Betaseron (interferon beta-1b)." Berlex, Richmond, CA.
- "Product Information. Rebif (interferon beta-1a)." Serono Laboratories Inc, Norwell, MA.
- "Product Information. Avonex (interferon beta-1a)." Biogen, Cambridge, MA.
Generic Name: onasemnogene abeparvovec
Brand name: Zolgensma, Zolgensma
Synonyms: Onasemnogene abeparvovec (Zolgensma)
Generic Name: peginterferon beta-1a
Brand name: Plegridy, Plegridy Pen, Plegridy Pen Starter Pack, Plegridy Starter Pack
Synonyms: Peginterferon Beta-1a
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Onasemnogene Abeparvovec-Peginterferon beta-1a Subcutaneous
- Onasemnogene Abeparvovec-PegIntron
- Onasemnogene Abeparvovec-Pegloticase
- Onasemnogene Abeparvovec-Pegloticase Intravenous
- Onasemnogene Abeparvovec-Pegvaliase
- Onasemnogene Abeparvovec-Pegvaliase-pqpz
- Peginterferon beta-1a-Onasemnogene abeparvovec Zolgensma
- Peginterferon beta-1a-Oncaspar
- Peginterferon beta-1a-Oncovin
- Peginterferon beta-1a-Ondansetron
- Peginterferon beta-1a-Ondansetron and Dextrose
- Peginterferon beta-1a-Ondansetron Hydrochloride